A heptapeptide analog of ACTH(4-10) extended with a Pro-Gly-Pro tail that confers protease resistance. It lacks the corticotropic activity of the parent hormone. Reported effects centre on increased BDNF and NGF expression in the hippocampus and modulation of monoaminergic systems — the basis for nootropic and neuroprotective claims.
Developed and clinically studied in Russia, where it is a registered medicine for stroke and cognitive indications. The trial literature is largely Russian-language and has not been subjected to Western regulatory review; methodological quality is difficult to assess from outside. Independent replication is limited.
Not FDA-approved. Registered as a medicine in Russia. Not lawfully marketed for human use in the US.
Russian clinical use suggests reasonable tolerability, but this rests on a literature that has not been independently audited. Long-term data unavailable.
Forge Bioenergy does not publish dosing, reconstitution, or administration protocols for any peptide. See our editorial policy for why. If you are considering any substance on this page, that conversation belongs with a licensed physician.
Regulatory status changes. This page reflects our reading of public sources as of July 2026 and should be independently verified before it is relied upon.